Biomea Fusion, Inc. - Common Stock (BMEA)

Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

U.S. futures were higher on Wednesday as oil futures tumbled after Donald Trump called for an "Unconditional Surrender" by Iran late Tuesday.

The offering follows early clinical data from Biomea’s BMF-500 leukemia program, which showed encouraging responses in heavily pretreated patients.

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Biomea Fusion is realigning its focus on diabetes and obesity programs, cutting 35% of its workforce and consolidating operations to reduce costs.

Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.

FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, allowing the ongoing studies to resume.

BMEA stock results show that Biomea Fusion beat analyst estimates for earnings per share the second quarter of 2024.